Фиброгенные и антифиброгенные факторы роста в развитии диабетической нефропатии

Автор: Бондарь И.А., Климонтов В.В., Парфентьева Е.М.

Журнал: Сибирский журнал клинической и экспериментальной медицины @cardiotomsk

Статья в выпуске: 4-2 т.26, 2011 года.

Бесплатный доступ

Прогрессирующий фиброз клубочков и тубулоинтерстиция почек - ведущий патологический процесс, определяющий развитие хронической почечной недостаточности при диабетической нефропатии (ДН). Формирование фиброза почек в условиях действия гипергликемии и других нефропатогенных факторов связано с нарушением баланса фиброгенных и антифиброгенных факторов роста, регулирующих процессы пролиферации, дифференцировки, апоптоза и синтетической функции клубочковых и канальцевых клеток. В условиях гипергликемии в почках наблюдается активация синтеза фиброгенных факторов роста (трансформирующий фактор роста β, фактор некроза опухолей α, фактор роста фибробластов, фактор роста соединительной ткани, фактор роста эндотелия сосудов) при одновременном подавлении продукции антифиброгенных факторов роста (костный морфогенетический протеин 7, фактор роста гепатоцитов). Дисбаланс в экспрессии и активности фиброгенных и антифиброгенных факторов роста имеет решающее значение для нарушения обмена компонентов внеклеточного матрикса и формирования гломерулярного и интерстициального фиброза при ДН. Факторы роста можно рассматривать как перспективные диагностические маркеры и потенциальные мишени для нефропротекции при диабетическом поражении почек.

Еще

Диабетическая нефропатия, факторы роста, внеклеточный матрикс, фиброз почек

Короткий адрес: https://sciup.org/14919618

IDR: 14919618

Список литературы Фиброгенные и антифиброгенные факторы роста в развитии диабетической нефропатии

Бондарь И.А., Климонтов В.В., Надеев А.П. Мочевая экскреция провоспалительных цитокинов и трансформирующего фактора роста β на ранних стадиях диабетической нефропатии//Тер. архив. -2008. -№ 1. -С. 52-56.
Бондарь И.А., Климонтов В.В., Рогова И.П. и др. Почки при сахарном диабете. -Новосибирск: Изд-во НГТУ, 2008. -С. 272.
Шестакова М.В., Дедов И.И. Сахарный диабет и хроническая болезнь почек. -М.: Мед. информ. агентство, 2009. -С. 482.
Adler S.G., Kang S.W., Feld S. et al. Glomerular mRNAs in human type 1 diabetes: biochemical evidence for microalbuminuria as a manifestation of diabetic nephropathy//Kidney Int. -2001. -[Vol.] 60 (6). -P. 2330-2336.
Baelde H.J., Eikmans M., Lappin D.W. et al. Reduction of VEGF A and CTGF expression in diabetic nephropathy is associated with podocyte loss//Kidney Int. -2007. -[Vol.] 71 (7). -P. 637-645.
Chen S., Kasama Y., Lee J. S. et al. Podocyte derived vascular endothelial growth factor mediates the stimulation of alpha3(IV) collagen production by transforming growth factor beta1 in mouse podocytes//Diabetes. -2004. -[Vol.] 53 (11). -P. 2939-2949.
Chen S., Jim B., Ziyadeh F.N. Diabetic nephropathy and transforming growth factor beta: transforming our view of glomerulosclerosis and fibrosis build up//Semin. Nephrol. -2003. -[Vol.] 23 (6). -P. 532-543.
Chen S., Ziyadeh F.N. Transforming growth factor β signal transduction in the pathogenesis of diabetic nephropathy//The Diabetic Kidney/ed. P. Cortes, C.E. Mogensen. -Totowa, NJ: Humana Press, 2006. -P. 527-548.
Dai C., Liu Y. Hepatocyte growth factor antagonizes the profibrotic action of TGF beta1 in mesangial cells by stabilizing Smad transcriptional corepressor TGF//J. Am. Soc. Nephrol. -2004. -[Vol.] 15 (6). -P. 1402-1412.
Dai C., Yang J., Bastacky S. et al. Intravenous administration of hepatocyte growth factor gene ameliorates diabetic nephropathy in mice//J. Am. Soc. Nephrol. -2004. -[Vol.] 15 (1). -P. 2637-2647.
De Petris L., Hruska K.A., Chiechio S. Bone morphogenetic protein 7 delays podocyte injury due to high glucose//Nephrol. Dial. Transplant. -2007. -[Vol.] 22 (12). -P. 3442-3450.
De Vriese A.S., Tilton R.G., Elger M. et al. Antibodies against vascular endothelial growth factor improve early renal dysfunction in experimental diabetes//J. Am. Soc. Nephrol. -2001. -[Vol.] 12 (5). -P. 993-1000.
Esposito C., Parrilla B., De Mauri A. et al. Hepatocyte growth factor (HGF) modulates matrix turnover in human glomeruli//Kidney Int. -2005. -[Vol.] 67 (6). -P. 2143-2150.
Flyvbjerg A., Dagnaes Hansen F., De Vriese A.S. et al. Amelioration of long term renal changes in obese type 2 diabetic mice by a neutralizing vascular endothelial growth factor antibody//Diabetes. -2002. -[Vol.] 51 (10). -P. 3090-3094.
Forbes J.M., Thallas V., Thomas M.C. et al. The breakdown of preexisting advanced glycation end products is associated with reduced renal fibrosis in experimental diabetes//FASEB J. -2003. -[Vol.] 17 (12). -P. 1762-1764.
Hellmich B., Schellner M., Schatz H. et al. Activation of transforming growth factor beta1 in diabetic kidney disease//Metabolism. -2000. -[Vol.] 49 (3). -P. 353-359.
Hohenstein B., Hausknecht B., Boehmer K. et al. Local VEGF activity but not VEGF expression is tightly regulated during diabetic nephropathy in man//Kidney Int. -2006. -[Vol.] 69 (9). -P. 1654-1661.
Huang S., Liu F., Sha Z. et al. Effect of high glucose, angiotensin II and receptor antagonist Losartan on the expression of connective tissue growth factor in cultured mesangial cells//Chin. Med. J. -2003. -[Vol.] 116 (4). -P. 554-557.
Hui L., Hong Y., Jingjing Z. et al. HGF suppresses high glucose mediated oxidative stress in mesangial cells by activation of PKG and inhibition of PKA//Free Radic. Biol. Med. -2010. -[Vol.] 49(3). -P. 467-473. -(URL: http://www.ncbi.nlm.nih.gov/pubmed/20466058).
Iglesias de la Cruz M.C., Ziyadeh F.N., Isono M. et al. Effects of high glucose and TGF beta1 on the expression of collagen IV and vascular endothelial growth factor in mouse podocytes//Kidney Int. -2002. -[Vol.] 62 (3). -P. 901-913.
Ikehara K., Tada H., Kuboki K. et al. Role of protein kinase C angiotensin II pathway for extracellular matrix production in cultured human mesangial cells exposed to high glucose levels//Diabetes Res. Clin. Pract. -2003. -[Vol.] 59 (1). -P. 25-30.
Kagawa T., Takemura G., Kosai K. et al. Hepatocyte growth factor gene therapy slows down the progression of diabetic nephropathy in db/db mice//Nephron. Physiol. -2006. -[Vol.] 102 (3-4). -P. 92-102.
Kalantarinia K., Awad A.S., Siragy H.M. Urinary and renal interstitial concentrations of TNF alpha increase prior to the rise in albuminuria in diabetic rats//Kidney Int. -2003. -[Vol.] 64 (4). -P. 1208-1213.
Kang Y.S., Park Y.G., Kim B.K. et al. Angiotensin II stimulates the synthesis of vascular endothelial growth factor through the p38 mitogen activated protein kinase pathway in cultured mouse podocytes//J. Mol. Endocrinol. -2006. -[Vol.] 36 (2). -P. 377-388.
Katavetin P., Miyata T., Inagi R. et al. High glucose blunts vascular endothelial growth factor response to hypoxia via the oxidative stress regulated hypoxia inducible factor/hypoxia responsible element pathway//J. Am. Soc. Nephrol. -2006. -[Vol.] 17 (5). -P. 1405-1413.
Kelly D.J., Buck D., Cox A.J. et al. Effects on protein kinase C beta inhibition on glomerular vascular endothelial growth factor expression and endothelial cells in advanced experimental diabetic nephropathy//Am. J. Physiol. Renal. Physiol. -2007. -[Vol.] 293 (2). -P. F565-F574.
Lee E.Y., Chung C.H., Kim J.H. et al. Antioxidants ameliorate the expression of vascular endothelial growth factor mediated by protein kinase C in diabetic podocytes//Nephrol. Dial. Transplant. -2006. -[Vol.] 21 (6). -P. 1496-1503.
Lin J., Hu F.B., Mantzoros C., Curhan G.C. Lipid and inflammatory biomarkers and kidney function decline in type 2 diabetes//Diabetologia. -2010. -[Vol.] 53 (2). -P. 263-267.
Min D., Lyons J.G., Bonner J. et al. Mesangial cell derived factors alter monocyte activation and function through inflammatory pathways: possible pathogenic role in diabetic nephropathy//Am. J. Physiol. Renal. Physiol. -2009. -[Vol.] 297 (5). -P. 1229-1237.
Mitu G., Hirschberg R. Bone morphogenetic protein 7 (BMP7) in chronic kidney disease//Front. Biosci. -2008. -[Vol.] 1 (13). -P. 4726-4739.
Mitu G.M, Wang S., Hirschberg R. BMP 7 is a podocyte survival factor and rescues podocytes from diabetic injury//Am. J. Physiol. Renal. Physiol. -2007. -[Vol.] 293 (5). -P. F1641-F1648.
Mizuno S., Nakamura T. Suppressions of chronic glomerular injuries and TGF beta 1 production by HGF in attenuation of murine diabetic nephropathy//Am. J. Physiol. Renal Physiol. -2004. -[Vol.] 286 (1). -P. F134-F143.
Navarro J.F., Milena F.J., Mora C. et al. Renal pro inflammatory cytokine gene expression in diabetic nephropathy: effect of angiotensin converting enzyme inhibition and pentoxifylline administration//Am. J. Nephrol. -2006. -[Vol.] 26 (6). -P. 562-570.
Ng D.P., Fukushima M., Tai B.C. et al. Reduced GFR and albuminuria in Chinese type 2 diabetes mellitus patients are both independently associated with activation of the TNF alpha system//Diabetologia. -2008. -[Vol.] 51 (12). -P. 2318-2324.
Nguyen T.Q., Roestenberg P., van Nieuwenhoven F.A. et al. CTGF inhibits BMP 7 signaling in diabetic nephropathy//J. Am. Soc. -2008. -[Vol.] 19 (11). -P. 2098-2107.
Niewczas M.A., Ficociello L.H., Johnson A.C. et al. Serum concentrations of markers of TNFalpha and Fas mediated pathways and renal function in non proteinuric patients with type 1 diabetes//Clin. J. Am. Soc. Nephrol. -2009. -[Vol.] 4 (1). -P. 62-70.
Onozaki A., Midorikawa S., Sanada H. et al. Rapid change of glucose concentration promotes mesangial cell proliferation via VEGF: inhibitory effects of thiazolidinedione//Biochem. Biophys. Res. Commun. -2004. -[Vol.] 317 (1). -P. 24-29.
Riser B.L., Cortes P., DeNichilo M. et al. Urinary CCN2 (CTGF) as a possible predictor of diabetic nephropathy: preliminary report//Kidney Int. -2003. -[Vol.] 64 (2). -P. 451-458.
Riser B.L., Fornoni A., Karoor S. Connective tissue growth factor in the pathogenesis of diabetic nephropathy//The Diabetic Kidney/ed. P. Cortes, C.E. Mogensen. -Totowa, N. J.: Humana Press, 2006. -P. 175-186.
Roestenberg P., van Nieuwenhoven F.A., Wieten L. et al. Connective tissue growth factor is increased in plasma of type 1 diabetic patients with nephropathy//Diabetes Care. -2004. -[Vol.] 27 (5). -P. 1164-1170.
Rossing P. The changing epidemiology of diabetic microangiopathy in type 1 diabetes//Diabetologia. -2005. -[Vol.] 48 (8). -P. 1439-1444.
Sahakyan K., Klein B., Lee K. et al. Inflammatory and endothelial dysfunction markers and proteinuria in persons with type 1 diabetes mellitus//Eur. J. Endocrinol. -2010. -[Vol.] 162 (6). -P. 1101-1105.
Santilli F., Spagnoli A., Mohn A. et al. Increased vascular endothelial growth factor serum concentrations may help to identify patients with onset of type 1 diabetes during childhood at risk for developing persistent microalbuminuria//J. Clin. Endocrinol. Metab. -2001. -[Vol.] 86 (8). -P. 3871-3876.
Schrijvers B.F., De Vriese A.S., Flyvbjerg A. From hyperglycemia to diabetic kidney disease: the role of metabolic, hemodynamic, intracellular factors and growth factors/cytokines//Endocr. Rev. -2004. -[Vol.] 25 (6). -P. 971-1010.
Siragy H.M., Awad A., Abadir P. et al. The angiotensin II type 1 receptor mediates renal interstitial content of tumor necrosis factor alpha in diabetic rats//Endocrinology. -2003. -[Vol.] 144 (6). -P. 2229-2233.
Song J.H., Cha S.H., Lee H.J. et al. Effect of low dose dual blockade of renin angiotensin system on urinary TGF beta in type 2 diabetic patients with advanced kidney disease//Nephrol. Dial. Transplant. -2006. -[Vol.] 21 (3). -P. 683-689.
Strutz F. The role of FGF 2 in renal fibrogenesis//Front. Biosci. (Schol. Ed.). -2009. -[Vol.] 1 (1). -P. 125-131.
Strutz F., Zeisberg M., Hemmerlein B. et al. Basic fibroblast growth factor expression is increased in human renal fibrogenesis and may mediate autocrine fibroblast proliferation//Kidney Int. -2000. -[Vol.] 57 (4). -P. 1521-1538.
Sugimoto H., Grahovac G., Zeisberg М. et al. Renal fibrosis and glomerulosclerosis in a new mouse model of diabetic nephropathy and its regression by bone morphogenic protein 7 and advanced glycation end product inhibitors//Diabetes. -2007. -[Vol.] 56 (7). -P. 1825-1833.
Thomson S.E., McLennan S.V., Kirwan P.D. et al. Renal connective tissue growth factor correlates with glomerular basement membrane thickness and prospective albuminuria in a non human primate model of diabetes: possible predictive marker for incipient diabetic nephropathy//J. Diabetes Complications 2008. -[Vol.] 22 (4). -P. 284-294.
van Nieuwenhoven F.A., Jensen L.J., Flyvbjerg A. et al. Imbalance of growth factor signalling in diabetic kidney disease: is connective tissue growth factor (CTGF, CCN2) the perfect intervention point?//Nephrol. Dial. Transplant. -2005. -[Vol.] 20 (1). -P. 6-10.
Vasko R., Koziolek M., Ikehata M. et al. Role of basic fibroblast growth factor (FGF 2) in diabetic nephropathy and mechanisms of its induction by hyperglycemia in human renal fibroblasts//Am. J. Physiol. Renal. Physiol. -2009. -[Vol.] 296 (6). -P. F1452-F1463.
Vendrell J., Broch M., Fernandez Real J.M. et al. Tumour necrosis factor receptors (TNFRs) in type 2 diabetes. Analysis of soluble plasma fractions and genetic variations of TNFR2 gene in a case control study//Diabet. Med. -2005. -[Vol.] 22 (4). -P. 387-392.
Veron D., Reidy K.J., Bertuccio C. et al. Overexpression of VEGF A in podocytes of adult mice causes glomerular disease//Kidney Int. -2010. -[Vol.] 77 (11). -P. 989-999.
Wang S., de Caestecker M., Kopp J. Renal bone morphogenetic protein 7 protects against diabetic nephropathy//J. Am. Soc. Nephrol. -2006. -[Vol.] 17 (9). -P. 2504-2512.
Wang S., Chen Q., Simon T.C. Bone morphogenic protein 7 (BMP 7), a novel therapy for diabetic nephropathy//Kidney Int. -2003. -[Vol.] 63 (6). -P. 2037-2049.
Wang S.N., Lapage J., Hirschberg R. Loss of tubular bone morphogenetic protein 7 in diabetic nephropathy//J. Am. Soc. Nephrol. -2001. -[Vol.] 12 (11). -P. 2392-2399.
Wang Y., Nagase S., Koyama A. Stimulatory effect of IGF I and VEGF on eNOS message, protein expression, eNOS phosphorylation and nitric oxide production in rat glomeruli, and the involvement of PI3 K signaling pathway//Nitric Oxide. -2004. -[Vol.] 10 (1). -P. 25-35.
Wendt T., Tanji N., Guo J. et al. Glucose, glycation, and RAGE: implications for amplification of cellular dysfunction in diabetic nephropathy//J. Am. Soc. Nephrol. -2003. -[Vol.] 14 (5). -P. 1383-1395.
Xia L., Wang H., Munk S. et al. Reactive oxygen species, PKC beta1, and PKC zeta mediate high glucose induced vascular endothelial growth factor expression in mesangial cells//Am. J. Physiol. Endocrinol. Metab. -2007. -[Vol.] 293 (5). -P. E1280-E1288.
Yang J., Dai C., Liu Y. A novel mechanism by which hepatocyte growth factor blocks tubular epithelial to mesenchymal transition//J. Am. Soc. Nephrol. -2005. -[Vol.] 16 (1). -P. 68-78.
Yang Q., Han B., Xie R.J., Cheng M.L. Changes of bone morphogenetic protein 7 and inhibitory Smad expression in streptozotocin induced diabetic nephropathy rat kidney//Sheng Li Xue Bao. -2007. -[Vol.] 25 (59). -P. 190-196.
Yeh C.H., Chang C.K., Cheng M.F. The antioxidative effect of bone morphogenetic protein 7 against high glucose induced oxidative stress in mesangial cells//Biochem. Biophys. Res. Commun. -2009. -[Vol.] 382 (2). -P. 292-297.
Yeh C.H., Chang C.K., Cheng M.F. et al. Decrease of bone morphogenetic protein 7 (BMP 7) and its type II receptor (BMP RII) in kidney of type 1 like diabetic rats//Horm. Metab. Res. -2009. -[Vol.] 41 (8). -P. 605-611.
Yokoi H., Mukoyama M., Mori K. et al. Overexpression of connective tissue growth factor in podocytes worsens diabetic nephropathy in mice//Kidney Int. -2008. -[Vol.] 73 (4). -P. 446-455.

Еще

Статья научная